AIM: The current accepted standard treatment for neovascular age-related macular degeneration (AMD) consists of antivascular endothelial growth factor agents including ranibizumab and bevacizumab. The aim of the study was to examine whether bevacizumab is inferior to ranibizumab with respect to maintaining/improving visual acuity. METHODS: In this prospective randomised parallel group multicentre trial patients aged more than 50 years with treatment naive nAMD were included at 10 Austrian centres. Patients were randomised to treatment either with 0.5 mg ranibizumab or 1.25 mg bevacizumab. Both groups received three initial monthly injections and thereafter monthly evaluation of visual acuity and the activity of the lesion. Re-treatment was scheduled as needed. Outcome measures were early treatment of diabetic retinopathy visual acuity, retinal thickness, lesion size and safety evaluation. RESULTS:A total of 321 patients were recruited of which four had to be excluded due to different reasons. Of the 317 remaining patients 154 were randomised into the bevacizumab group and 163 into the ranibizumab group. At month 12, there was a mean increase of early treatment of diabetic retinopathy visual acuity of 4.9 letters in the bevacizumab and 4.1 letters in the ranibizumab group (p=0.78). Furthermore, there were no significant differences in the decrease of retinal thickness, change of lesion size and number of adverse events between the groups. CONCLUSIONS:Bevacizumab was equivalent to ranibizumab for visual acuity at all time points over 1 year. There was no significant difference of decrease of retinal thickness or number of adverse events.
RCT Entities:
AIM: The current accepted standard treatment for neovascular age-related macular degeneration (AMD) consists of antivascular endothelial growth factor agents including ranibizumab and bevacizumab. The aim of the study was to examine whether bevacizumab is inferior to ranibizumab with respect to maintaining/improving visual acuity. METHODS: In this prospective randomised parallel group multicentre trial patients aged more than 50 years with treatment naive nAMD were included at 10 Austrian centres. Patients were randomised to treatment either with 0.5 mg ranibizumab or 1.25 mg bevacizumab. Both groups received three initial monthly injections and thereafter monthly evaluation of visual acuity and the activity of the lesion. Re-treatment was scheduled as needed. Outcome measures were early treatment of diabetic retinopathy visual acuity, retinal thickness, lesion size and safety evaluation. RESULTS: A total of 321 patients were recruited of which four had to be excluded due to different reasons. Of the 317 remaining patients 154 were randomised into the bevacizumab group and 163 into the ranibizumab group. At month 12, there was a mean increase of early treatment of diabetic retinopathy visual acuity of 4.9 letters in the bevacizumab and 4.1 letters in the ranibizumab group (p=0.78). Furthermore, there were no significant differences in the decrease of retinal thickness, change of lesion size and number of adverse events between the groups. CONCLUSIONS:Bevacizumab was equivalent to ranibizumab for visual acuity at all time points over 1 year. There was no significant difference of decrease of retinal thickness or number of adverse events.
Authors: Stephanie A Hagstrom; Gui-shuang Ying; Gayle J T Pauer; Gwen M Sturgill-Short; Jiayan Huang; Maureen G Maguire; Daniel F Martin Journal: JAMA Ophthalmol Date: 2014-05 Impact factor: 7.389
Authors: Stanford C Taylor; Julia B Huecker; Mae O Gordon; David E Vollman; Rajendra S Apte Journal: JAMA Ophthalmol Date: 2016-08-01 Impact factor: 7.389
Authors: L Tiosano; O Segal; N Mathalone; A Pollack; R Ehrlich; I Klemperer; Y Barak; I Moroz; I Chowers; M Goldstein Journal: Eye (Lond) Date: 2017-02-17 Impact factor: 3.775
Authors: Frank Enseleit; Stephan Michels; Isabella Sudano; Marc Stahel; Sandrine Zweifel; Oliver Schlager; Matthias Becker; Stephan Winnik; Matthias Nägele; Andreas J Flammer; Michel Neidhart; Nicole Graf; Christian M Matter; Burkhardt Seifert; Thomas F Lüscher; Frank Ruschitzka Journal: Ophthalmologica Date: 2017-09-02 Impact factor: 3.250